- SOHO 2023
- SOHO 2022
- SOHO 2021
- SOHO 2020
- SOHO Highlights: State of the Art and Next Questions
-
SOHO 2019
Hodgkin Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia Meet The Professor Sessions Chronic Myeloid Leukemia Myeloproliferative Neoplasms Breakfast With The Expert Independent Satellite Symposium Plenary Sessions Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options Acute Lymphoblastic Leukemia Myelodysplastic Syndromes Acute Myeloid Leukemia Indolent B-cell Lymphoma Mantle Cell Lymphoma Aggressive B-cell Lymphoma T-cell Lymphoma Cellular Therapy Next Questions
-
SOHO 2018
Session I: Chronic Myeloid Leukemia Session II: Myelodysplastic Syndromes Session III: Myeloproliferative Neoplasms Session IV: Acute Lymphoblastic Leukemia Session V: Acute Myeloid Leukemia Session VI: Multiple Myeloma Session VIII: Non-Hodgkin Lymphoma Session IX: Chronic Lymphocytic Leukemia Session X: Research Topics Plenary Sessions Breakfast with the Expert
- Events
Playback speed
10 seconds
2020 SOHO Highlights on CD123 in AML: What Determines Sensitivity and Resistance to Tagraxofusp? Does the Addition of Azacitidine Affect the Therapy?
0 views
November 13, 2020
Comments 0
Login to view comments.
Click here to Login
Leukemia